CURRENT NEWS

• 28.01.2020
  NantHealth and NantOmics Reveal a Novel AI Based Machine-Learning Digital Pathology Software for Lung Cancer by Identifying Tumor Infiltrating Killer Cells From Whole Slide Images
• 27.01.2020
  PharmaCielo Announces 30,000 Kg Cannabis Extract Agreement for German Market
• 27.01.2020
  Reig Jofre Reaches a New Milestone: 5 Million Vials of Injectable Remifentanil Marketed in Japan
• 27.01.2020
  GEA Group AG Has Recognized Non-Cash Impairments in the Fourth Quarter of 2019 and Accelerates the Recognition of Restructuring Expenses - Group Forecast Unchanged
• 27.01.2020
  Biocon's API Manufacturing Facility Completes Pre-Approval and GMP U.S. FDA Inspection
• 27.01.2020
  IntelGenx Announces Pricing of Equity Offering
• 27.01.2020
  Jubilant Radiopharma Receives Approval From Health Canada for Drax Exametazime
• 27.01.2020
  BIOTRONIK, Inc. Appoints David Hayes, MD, as Chief Medical Officer
• 27.01.2020
  Enteris BioPharma Receives 2019 Best of Boonton Award
• 27.01.2020
  IBEX Grants Stock Options
• 27.01.2020
  Lupin's Pithampur Facilities Complete Successful MHRA Inspection
• 27.01.2020
  Accreditation of the WHO European Regional Reference Laboratory for Measles and Rubella at LIH
• 27.01.2020
  Twist Bioscience Announces Completion of $50 Million Registered Direct Offering Priced At-The-Market
• 27.01.2020
  AVEO Oncology and Biodesix Announce Results From Phase 1b Study of Ficlatuzumab, Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Cancer
• 27.01.2020
  Otsuka Announces Positive Top-Line Results from Clinical Trials in Japan of Fremanezumab as a Prophylactic Treatment for Migraine
• 27.01.2020
  AFFiRiS Announces FDA Response to Its Pre-Ind Submission for Phase 2 Trial With AFFITOPE PD01 in Early Parkinson's Disease Patients
• 27.01.2020
  Epygenix Therapeutics Successfully Completes EPX-100 Phase I, Placebo-Controlled, Double-Blind, 2-Period Study and Ready to Phase 2 Studies
• 27.01.2020
  Introduction of Lorazepam Prolepha 0.5 Mg Tablets
• 25.01.2020
  Scant Evidence for Mesoblast's Stem Cell Candidate in Treating Pain, Say Experts
• 25.01.2020
  NantHealth's Eviti Connect Data Shows Recycling of Chemotherapy and Biologics for Advanced CRC Patients More Common Than Switching to Drug Regimens With Alternative Mechanism of Action

Records per page:

Page

Total: 15738 records.